3347-99-7

Usage

Uses

Used in Polymer and Resin Production:
5-Methylisophthalic acid is used as a key component in the production of polymers and resins, contributing to their enhanced properties and performance. Its unique structure allows for the creation of materials with improved characteristics, such as increased strength, durability, and resistance to various environmental factors.
Used in the Manufacturing of Fibers, Films, and Plastics:
As a crucial ingredient in the production of polyesters, 5-methylisophthalic acid is used in the manufacturing of fibers, films, and plastics. These materials are widely used in various industries, including textiles, packaging, and consumer goods, due to their desirable properties such as lightweight, flexibility, and resistance to wear and tear.
Used in the Synthesis of Organic Compounds and Pharmaceuticals:
5-Methylisophthalic acid serves as a building block in the synthesis of various organic compounds and pharmaceuticals. Its unique chemical properties make it a valuable precursor in the development of new drugs and other chemical products, contributing to advancements in medicine and other fields.
Used in Chemical and Polymer Industries:
5-Methylisophthalic acid is extensively used in the chemical and polymer industries, where its versatile properties are harnessed to create a wide range of products. Its applications in these industries are diverse, including the production of specialty polymers, coatings, adhesives, and other materials that are essential to various sectors, such as automotive, construction, and electronics.

Upstream product

• 95-63-6 1,2,4-Trimethylbenzene 
• 2142-73-6 1-(2,5-dimethylphenyl)-1-ethanone 
• 1202-08-0 2-methyl-5-isopropylacetophenone 
• 1943-88-0 2,4-dicyanotoluene 
• 90673-66-8 (4-methyl-1,3-phenylene)dimethanol 
• 121-04-0 toluene-2,4-disulfonic acid 
• 141-53-7 sodium formate 
• 40207-05-4 3-(chloromethyl)-4-methylbenzoic acid 
• 75-44-5 phosgene 
• 99-94-5 p-Toluic acid 
• 610-72-0 2,5-dimethylbenzoic acid 
• 95-73-8 2,4-dichlorotoluene 
• 544-92-3 copper(I) cyanide 
• 124-38-9 carbon dioxide 

Downstream Products

• 35539-00-5 5-hydroxy-4-methyl-isophthalic acid 
• 23038-61-1 dimethyl 4-methylbenzene-1,3-dicarboxylate 
• 96259-57-3 diethyl 4-methylisophthalte 
• 16281-94-0 dimethyl 4-bromomethylbenzene-1,3-dicarboxylate 
• 96259-66-4 diethyl 4-methyl-1,3-cyclohexanedicarboxylate 
• 96259-71-1 diethyl 4-(bromomethyl)isophthalate 
• 1417404-25-1 C₂₆H₂₂F₂N₂O₃ 
• 1417403-96-3 4-[2-(3-chlorophenyl)ethyl]isophthalic acid dimethyl ester 
• 1417404-26-2 C₂₈H₂₇F₂N₃O₃ 
• 1417404-27-3 8-((3-benzamido-4-fluorophenyl)amino)-N-(2-morpholinoethyl)-5-oxo-10,11-dihydro-5H-dibenzo[a,d][7]annulene-3-carboxamide 

Relevant academic research and scientific papers

CENTRALLY ACTIVE P38ALPHA INHIBITING COMPOUNDS

Compounds that are inhibitors of p38alpha and centrally available are described.

Method for preparing aromatic carboxylic acid compound

The invention discloses a method for preparing an aromatic carboxylic acid compound. The method comprises the following steps: 1) heating carbon dioxide and hydrosilane in the presence of a copper catalyst in a reaction medium A; and 2) adding a reaction medium B, aryl halide, a palladium catalyst and a base to the reaction mixture in the step 1), sealing the reaction system, and performing a heating reaction. The method has the advantages that raw materials are simple and easy to obtain, the raw materials are cheap and stable, the catalyst is common, easy to obtain and stable, the reaction conditionsaremild, the aftertreatment is simple, the yield is high, and the like.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF RAS AND METHODS OF USE THEREOF

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, B, R", Q, W, X, Y, Z, n1, n2and '--" are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also disclosed.

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine

We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.

Inclusion complex containing epoxy resin composition for semiconductor encapsulation

The invention is an epoxy resin composition for sealing a semiconductor, including (A) an epoxy resin and (B) a clathrate complex. The clathrate complex is one of (b1) an aromatic carboxylic acid compound, and (b2) at least one imidazole compound represented by formula (II): wherein R2 represents a hydrogen atom, C1-C10 alkyl group, phenyl group, benzyl group or cyanoethyl group, and R3 to R5 represent a hydrogen atom, nitro group, halogen atom, C1-C20 alkyl group, phenyl group, benzyl group, hydroxymethyl group or C1-C20 acyl group. The composition has improved storage stability, retains flowability when sealing, and achieves an effective curing rate applicable for sealing delicate semiconductors.

Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low ATP competitiveness and outstanding whole blood activity

p38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases. Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market. This might be attributed to the fact that there is no inhibitor which combines outstanding activity in biological systems and selectivity. Herein an approach to the development of such inhibitors on the basis of the highly selective molecular probe Skepinone-L is described. Introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compounds. Hydrophilic moieties, addressing the solvent-exposed area adjacent to hydrophilic region II, conserved a high activity of the compounds in a whole blood assay. Combined with their outstanding selectivity and low ATP competitiveness, these inhibitors are very interesting candidates for use in biological systems and in therapy.

NOVEL ISOINDOLINONE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST T-TYPE CALCIUM CHANNEL AND METHOD FOR PREPARATION THEREOF

Disclosed are isoindolinone derivatives, represented by Chemical Formula 1, having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient. wherein R1?R6 are as defined in the specification.

NOVEL ISOINDOLINONE DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST T-TYPE CALCIUM CHANNEL AND METHOD FOR PREPARATION THEREOF

Disclosed are isoindolinone derivatives having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient

DIPEPTIDYL PEPTIDASE-IV INHIBITORS

The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.

Methods of making 2,6-diaryl piperidine derivatives

Methods for preparing 2,6-diaryl piperidine derivatives are described. More particularly, 2,6-diaryl piperidines having formula 1-4 are prepared by cyclocondensation of an aryl or heteroaryl aldehyde with 1,3-acetonedicarboxylic acid.